Status:
COMPLETED
Early neo2 Registry of the Acurate neo2 TAVI Prosthesis
Lead Sponsor:
Andreas Rück
Collaborating Sponsors:
Boston Scientific Corporation
Conditions:
Aortic Valve Stenosis
Eligibility:
All Genders
Brief Summary
The Early neo2 registry will study up to 500 patients treated with the updated Boston Acurate neo2 TAVI prosthesis at various European hospitals. The data is gathered from routine healthcare and there...
Detailed Description
Background and rationale The Boston Scientific Acurate neo2 TAVI prosthesis was launched commercially in Europe in September 2020 as a successor to the original Acurate neo prosthesis. Modifications i...
Eligibility Criteria
Inclusion
- that a Acurate neo2 prosthesis has been inserted into the sheath (i.e. a procedure has been started).
Exclusion
- None
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2022
Estimated Enrollment :
554 Patients enrolled
Trial Details
Trial ID
NCT04810195
Start Date
September 1 2020
End Date
March 15 2022
Last Update
October 5 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark
2
Kerckhoff Klinik
Bad Nauheim, Germany
3
Lund University Hospital
Lund, Sweden
4
Karolinska University Hospital
Stockholm, Sweden